Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04513028 · ClinicalTrials.gov registry record · NA
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
A NA study of Melanoma Stage IV and Melanoma Stage III, sponsored by Kelly McMasters.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04513028: Recruiting NA study of Melanoma Stage IV and Melanoma Stage III, sponsored by Kelly McMasters.
NCT04513028 is a NA study of Melanoma Stage IV and Melanoma Stage III that is actively recruiting participants, run by Kelly McMasters. The registered enrollment target is 30 participants, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04513028, a NA study of Melanoma Stage IV and Melanoma Stage III, is actively recruiting participants, sponsored by Kelly McMasters.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.
Primary Outcome
The investigators will quantify percent of lymphocyte cell surface e (i.e., CD45, CD3, CD11b, etc.) from each sample collected by mass cytometry \*CyTOF) or flow cytometry
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Beta-Glucan
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2027-01-15 |
| Phase | NA |
What NCT04513028 shows while recruiting
NCT04513028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 101-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 1 intervention - of which Beta-Glucan is the first listed.
NCT04513028 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT04513028 about?
NCT04513028 is a clinical study titled "Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma". The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.
What is the current status of trial NCT04513028?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2020-11-03. Estimated completion is 2027-01-15.
What conditions does trial NCT04513028 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III.
What interventions are being tested in trial NCT04513028?
The interventions under investigation include: Beta-Glucan (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04513028?
This trial is sponsored by Kelly McMasters, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04513028 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04513028's enrollment target sits among peer trials
30 14th of 17 higher than 4 of 17 other Melanoma Stage IV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma Stage IV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
RECRUITING · Phase 2
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
RECRUITING · Early Phase 1
-
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
RECRUITING · Phase 2
-
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI